With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...
StockStory.org on MSN10h
Why Gilead Sciences (GILD) Stock Is Trading Up TodayWhat Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the ...
TD Cowen increased its price target on Gilead Sciences (NASDAQ:GILD) shares to $100 from the previous $95, while maintaining a Buy rating on the stock. The biotech giant, currently trading near its 52 ...
Shares of Super Micro Computer jumped after the company set a sales outlook for fiscal 2026 that blows past current Wall Street forecasts, unwinding a selloff earlier in the day.
Shares of Gilead Sciences ( GILD 7.46%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big ...
A change in Medicare policy is expected to flatten revenue from Gilead Science's HIV products, one of its most profitable segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback